Hong Kong IT Stock News

Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after announcing that its radionuclide drug candidate GPN01530-2 for solid tumor diagnosis has received Fast Track Designation from the United States Food and Drug Administration. See our latest analysis for Grand Pharmaceutical Group. The FDA Fast Track news has arrived during a mixed period for Grand Pharmaceutical Group's stock. The latest share price of HK$5.345 comes after a 1-day share price return of 2.00%, while the...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Axera Semiconductor Co., LTD. ( HKG:600 ) is possibly approaching a major achievement in its business, so we would like...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Samsonite Group (SEHK:1910) is in focus after half year 2026 results showed sales of US$1,680.6 million with lower net income, alongside guidance that third quarter constant currency sales growth should remain broadly similar to the second quarter. See our latest analysis for Samsonite Group. The latest guidance appears to have done little to lift sentiment, with Samsonite Group’s 1-day share price return of 1.44% only partly offsetting a year to date share price decline of 32.95%, while the...

Tencent earnings, AI spending and what they mean for investors Tencent Holdings (SEHK:700) has moved back into focus after second quarter 2026 earnings, continued heavy investment in artificial intelligence and the wider rollout of its Hy3 model put profitability and long term growth plans under scrutiny. See our latest analysis for Tencent Holdings. Tencent Holdings shares closed at HK$446.4, with the stock posting a 1-day share price return of 1.45% after earnings. It remains down 28.35% on...

Why Ma Chengdong’s Appointment Matters For Jinhai Medical Technology Jinhai Medical Technology (SEHK:2225) has appointed industry veteran Ma Chengdong as chief marketing officer for an initial one year term, with responsibilities spanning marketing strategy, market access and commercialisation of medical devices. For you as an investor, this kind of leadership change is less about the job title and more about what it could mean for how the company positions and sells its products. The...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

In recent months, Asian markets have experienced a mix of volatility and opportunity, with key indices reflecting a dynamic economic landscape influenced by global inflation trends and geopolitical tensions. As investors navigate these conditions, the search for promising small-cap stocks becomes crucial, particularly those that exhibit strong fundamentals and potential for growth amid insider activity.

Onewo Inc. ( HKG:2602 ) came out with its half-yearly results last week, and we wanted to see how the business is...

A blockbuster SpaceX IPO at more than US$1.8t has suddenly made the sleepy IPO market feel interesting again. Fresh talk of large AI listings and heavier spending on data centres is putting capital markets firms back in focus, and investors do not want to be late if deal fees recover meaningfully. This article walks through 3 stocks exposed to this IPO revival story and what that could mean for your portfolio. The three stocks covered below are only a starting sample, since the full screen...

Xiaomi (SEHK:1810) stock has drawn attention after recent trading performance showed mixed returns. The share price is around HK$25.88, with the company’s different business segments giving investors several angles to assess its current valuation. See our latest analysis for Xiaomi. Recent trading in Xiaomi reflects pressure on the share price over 2026, with the 90 day share price return down 15.54% and the year to date share price return down 35.75%, even though the 3 year total shareholder...

Morimatsu International Holdings (SEHK:2155) has guided for a consolidated loss of RMB150,000,000 to RMB180,000,000 for the first half of 2026, compared with a profit in the same period last year. See our latest analysis for Morimatsu International Holdings. Morimatsu International Holdings’ HK$7.64 share price has had mixed momentum, with a 30 day share price return of 5.23% but a year to date share price decline of 16.59%. The 3 year total shareholder return of 55.45% contrasts with a 1...

Pacific Basin Shipping (SEHK:2343) has drawn attention after reporting half year sales of US$1,105.48 million and net income of US$105.05 million, alongside declaring an ordinary interim dividend of HK$0.155 per share. See our latest analysis for Pacific Basin Shipping. The latest earnings, dividend and buyback updates come after a strong run in Pacific Basin Shipping's stock, with a 69.07% year to date share price return and an 84.64% total shareholder return over one year, suggesting...

China Petroleum & Chemical stock reaction to new PVA capacity China Petroleum & Chemical (SEHK:386) has completed commissioning of a specialty polyvinyl alcohol facility at Chongqing SVW Chemical, creating the world’s largest single site for high end PVA production capacity. The new 50,000 metric ton unit takes total site capacity to 210,000 metric tons a year and supports materials used in photovoltaics, electronics, optical films and pharmaceuticals, with first shipments already sent to...

With rate hike expectations cooling after softer U.S. data and the dollar slipping from recent highs, attention is swinging back to assets that many investors treat as potential hedges when policy and currency trends start to shift. That mix of weaker retail sales, firmer global equities and a softer dollar is creating fresh fear of missing out for anyone underexposed to these themes. This article walks through three stocks from a Gold and Precious-Metals Equity Hedges screener that appear...

Genscript Biotech stock has almost doubled over the past 3 months, yet today’s H1 print reminds you that the share price is racing ahead of a business still working through heavy losses. The headline is simple. Revenue sits at US$404.2m for the half while the company posted a net loss of US$129.3m and remains unprofitable on a trailing basis. The real tension for investors is the valuation. At HK$26.08, Genscript Biotech trades on an 8.6x P/S multiple with a discounted cash flow reference...

Global trade is quietly being rewired as AI moves from chatbots to control systems that track every container, document, and sanction screen. That shift is turning compliance data and traceability into a kind of trust currency. Investors who ignore it risk missing companies that sit at the heart of this transition. This article unpacks three stocks exposed to this trend and how the recent news backdrop could matter for each. The stocks covered below are just a sample, and the full screen...

SINOPEC Engineering (Group) closed at HK$5.18 after a weak few months, with the stock down about 11% over the past quarter. The market has been cooling on the story just as the latest half year numbers put profitability under more pressure. Net profit margins over the last year sit at 2.1%, down from 3.8%, while the trailing P/E multiple of 12.6x still leans above peer levels. For short term traders, that margin squeeze is the headline. For longer term holders, the key question now is whether...

HKBN (SEHK:1310) is back in focus after a leadership reshuffle that places Shen Qingyi in three key positions. He becomes Group CFO, executive director and a member of the remuneration committee. See our latest analysis for HKBN. The leadership changes at HKBN arrive after a mixed share price pattern, with a 1 month share price return of 4.55% but a 3 month decline of 13.07%. At the same time, the 1 year total shareholder return of 26.32% and 3 year total shareholder return of 89.96% suggest...

Global markets have shown mixed performance recently, with easing inflation concerns and AI-related earnings news providing some optimism amidst rising oil prices and geopolitical uncertainties. For investors looking beyond the major indices, penny stocks offer a unique opportunity to explore smaller or newer companies that might not be on everyone's radar. While the term 'penny stock' may seem outdated, these investments can still present significant potential when they are backed by strong...

As global markets navigate mixed signals from easing inflation concerns and ongoing geopolitical tensions, investors are increasingly turning their attention to dividend stocks as a potential source of steady income amid uncertainty. With major indices like the S&P 500 showing modest gains and others such as the Dow Jones Industrial Average finishing lower, selecting dividend stocks that demonstrate resilience and consistent payouts can be an appealing strategy in today's fluctuating economic...

Why Nexteer Automotive Group stock is in focus after half year earnings Nexteer Automotive Group (SEHK:1316) is back on investors’ radar after reporting half year 2026 results, with higher sales of US$2,328.84 million and net income of US$85.81 million compared with the prior year period. See our latest analysis for Nexteer Automotive Group. The half year earnings announcement appears to have shifted sentiment around Nexteer Automotive Group, with the 30 day share price return of 28.50% and 7...